In today’s recent session, 6.22 million shares of the Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have been traded, and its beta is 1.17. Most recently the company’s share price was $0.35, and it changed around -$0.06 or -12.86% from the last close, which brings the market valuation of the company to $19.44M. MRNS at last check was trading at a discount to its 52-week high of $11.26, offering almost -3117.14% off that amount. The share price’s 52-week low was $0.26, which indicates that the recent value has risen by an impressive 25.71% since then. We note from Marinus Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 9.6 million shares, with the 3-month average coming to 1.93 million.
Marinus Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.40. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended MRNS as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Marinus Pharmaceuticals Inc is expected to report earnings per share of -0.41 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS has been showing red trend so far today with a performance of -12.86% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8400 on recent trading dayincreased the stock’s daily price by 80.98%. The company’s shares are currently down -96.75% year-to-date, but still down -80.60% over the last five days. On the other hand, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is -80.82% down in the 30-day period. We can see from the shorts that 3.49 million shares have been sold at a short interest cover period of 4.89 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 88.33% from its current value. Analyst projections state that MRNS is forecast to be at a low of $2 and a high of $6.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Marinus Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -74.79 percent over the past six months and at a 22.81% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 32.80% in revenue this quarter, and will report an increase of 62.20% in the next quarter. The year-over-year growth rate is expected to be 18.40%, up from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 9.42M in revenue for the current quarter. 10 analysts expect Marinus Pharmaceuticals Inc to make 11.53M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 7.34M and 7.19M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 28.40%. Forecasts for the next quarter put sales growth at 60.40%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.04%. Marinus Pharmaceuticals Inc earnings are expected to increase by 26.21% in 2024, but the outlook is positive 20.00% per year for the next five years.
MRNS Dividends
Marinus Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Nov-05.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.96% of Marinus Pharmaceuticals Inc shares, and 81.89% of them are in the hands of institutional investors. The stock currently has a share float of 82.68%. Marinus Pharmaceuticals Inc stock is held by 111.0 institutions, with TANG CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 8.443% of the shares, which is about 4.8 million shares worth $5.62 million.
SOFINNOVA INVESTMENTS, INC., with 7.3025% or 4.15 million shares worth $4.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove were the top two Mutual Funds as of Jun 30, 2024. The former held 1.73 shares worth $0.62 million, making up 3.14% of all outstanding shares. On the other hand, Franklin Strategic Series-Franklin Biotechnology Discove held roughly 1.2 shares worth around $0.43 million, which represents about 2.18% of the total shares outstanding.
